10-Q quarterly report · filed Nov 4, 2026

Bio-rad Laboratories Inc (BIO) Q3 2026 10-Q Quarterly Report

Short answer

Bio-rad Laboratories Inc (BIO) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $656M (up 0.5% year over year) with net income of $459M.

Q3 2026 key financials · XBRL

Revenue
$656M
+0.5% YoY · +0.8% QoQ
Net income
$459M
+234.1% YoY · +23.5% QoQ
Operating margin
-7.6%
Gross margin
50.1%
EPS (diluted)
$17.05
+237.7% YoY · +24.0% QoQ

Source: XBRL data from the Bio-rad Laboratories Inc (BIO) Q3 2026 10-Q on SEC EDGAR. USD.

Bio-rad Laboratories Inc Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $656.4M, up 0.5% YoY from $653.0M, driven by Clinical Diagnostics
  • Clinical Diagnostics revenue $401.8M, up 2.7% YoY; Life Science $254.6M, down 2.8%
  • Gross margin 50.1% vs 52.6% YoY; SG&A margin 39.2% vs 31.7%
  • Operating cash flow $303.2M vs $367.3M; cash, equivalents and short-term investments $1.66B
  • Restructuring charges $77.6M; expected annual savings $30M to $35M by end-2027, with EMEA headwinds continuing

Risk Factors

  • Newly added AI risk: generative AI may expose confidential information or generate infringing content amid evolving regulation
  • Most material market update: aggressive pricing in multi-year public tenders, reducing annual tender opportunities and pressuring margins
  • Regulatory risk: future LDT legislation could impose FDA-style requirements on customers using Bio-Rad life science products
  • Operational risk: Middle East conflicts disrupting logistics, fuel costs and regional sales
  • Financial risk: $1.2 billion debt, including $400 million due March 2027 and $800 million due March 2032

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Bio-rad Laboratories Inc quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.